Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients
<h4>Background</h4> The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/?tool=EBI |
| _version_ | 1818282369241579520 |
|---|---|
| author | Sebastian A. Omenai Mustapha A. Ajani Clement A. Okolo |
| author_facet | Sebastian A. Omenai Mustapha A. Ajani Clement A. Okolo |
| author_sort | Sebastian A. Omenai |
| collection | DOAJ |
| description | <h4>Background</h4> The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated the immunohistochemical expression of PD-L1 in uterine cervical carcinomas. Women with cervical cancer would benefit from its use as a marker in therapy and prognosis. <h4>Methods</h4> Hospital-based cross-sectional retrospective study was conducted. The study materials included 183 archived formalin fixed and paraffin embedded (FFPE) tissue blocks with histological diagnosis of cervical carcinoma diagnosed in our facility within a five-year period (January 2012 and December 2016) that met the study criteria. Data were extracted from records in the Department and immunohistochemistry was done using polyclonal antibodies to PD-L1 (GTX104763, Genetex). Obtained data were analysed using SPSS version 23. P < 0.05 was considered significant. <h4>Results</h4> A hundred and eighty-three cases of cervical cancer were studied. PD-L1 was positive in 57.4% of all cases. The diffuse pattern of staining was the major pattern accounting for 88.5% of positive cases. Poorly differentiated cervical carcinomas are less likely to express PD-L1. Within the histologic types, the squamous cell carcinomas expressed PD-L1 in 58.7%, and 50% of adenocarcinomas were positive. PD-L1 was not expressed in all cases of adenoid cystic carcinomas and basaloid squamous cell carcinomas. <h4>Conclusion</h4> A significant population of cervical carcinoma expresses PD-L1 by immunohistochemistry. PD-L1 prevalence is lower amongst the poorly differentiated cancers compared to other grades. |
| first_indexed | 2024-12-13T00:19:55Z |
| format | Article |
| id | doaj.art-7e80078a20314ef6a250294050f80793 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T00:19:55Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7e80078a20314ef6a250294050f807932022-12-22T00:05:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01172Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patientsSebastian A. OmenaiMustapha A. AjaniClement A. Okolo<h4>Background</h4> The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated the immunohistochemical expression of PD-L1 in uterine cervical carcinomas. Women with cervical cancer would benefit from its use as a marker in therapy and prognosis. <h4>Methods</h4> Hospital-based cross-sectional retrospective study was conducted. The study materials included 183 archived formalin fixed and paraffin embedded (FFPE) tissue blocks with histological diagnosis of cervical carcinoma diagnosed in our facility within a five-year period (January 2012 and December 2016) that met the study criteria. Data were extracted from records in the Department and immunohistochemistry was done using polyclonal antibodies to PD-L1 (GTX104763, Genetex). Obtained data were analysed using SPSS version 23. P < 0.05 was considered significant. <h4>Results</h4> A hundred and eighty-three cases of cervical cancer were studied. PD-L1 was positive in 57.4% of all cases. The diffuse pattern of staining was the major pattern accounting for 88.5% of positive cases. Poorly differentiated cervical carcinomas are less likely to express PD-L1. Within the histologic types, the squamous cell carcinomas expressed PD-L1 in 58.7%, and 50% of adenocarcinomas were positive. PD-L1 was not expressed in all cases of adenoid cystic carcinomas and basaloid squamous cell carcinomas. <h4>Conclusion</h4> A significant population of cervical carcinoma expresses PD-L1 by immunohistochemistry. PD-L1 prevalence is lower amongst the poorly differentiated cancers compared to other grades.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/?tool=EBI |
| spellingShingle | Sebastian A. Omenai Mustapha A. Ajani Clement A. Okolo Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients PLoS ONE |
| title | Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients |
| title_full | Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients |
| title_fullStr | Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients |
| title_full_unstemmed | Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients |
| title_short | Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients |
| title_sort | programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/?tool=EBI |
| work_keys_str_mv | AT sebastianaomenai programmedeathligand1expressionsasasurrogatefordeterminingimmunotherapyincervicalcarcinomapatients AT mustaphaaajani programmedeathligand1expressionsasasurrogatefordeterminingimmunotherapyincervicalcarcinomapatients AT clementaokolo programmedeathligand1expressionsasasurrogatefordeterminingimmunotherapyincervicalcarcinomapatients |